ReviewInternational journal of molecular sciences2017
Regenerative Therapies in Dry Eye Disease: From Growth Factors to Cell Therapy.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Efficacy and safety of stem cell therapy for dry eye disease: a systematic review and meta-analysis.Stem cell research & therapy · 2026Pooled it
- Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study.Clinical ophthalmology (Auckland, N.Z.) · 2021Trial
- Immune inflammatory targets and anti-inflammatory therapy in dry eye disease.International ophthalmology · 2026Review
- Beyond the Cornea: Systemic Diseases and Their Impact on Endothelial Health-A Narrative Review.Journal of clinical medicine · 2026Review
- Cyclosporine Dissolution Test from a Lipid Dosage Form: Next Step Towards the Establishment of Release Method for Solid Lipid Microparticles.Pharmaceutics · 2025Article
- Stability of BTI Devices for Plasma Rich in Growth Factors (PRGF) Eye Drop Delivery Under Varying Storage and Handling Conditions.Biomedicines · 2025Article
- Injectable homologous platelet-rich plasma, alone or in combination with oral omega-3 supplementation, for treating keratoconjunctivitis sicca in dogs.Veterinary world · 2025Article
- Identification of glutamine as a potential therapeutic target in dry eye disease.Signal transduction and targeted therapy · 2025Article
- Progress and Prospects in the Treatment of Lacrimal Gland Dysfunction Diseases: From Traditional Treatment Methods to Stem Cell and Organoid Therapies.Stem cells international · 2025Review
- Molecular Mechanisms Responsible for Mesenchymal Stem Cell-Dependent Attenuation of Tear Hyperosmolarity and Immune Cell-Driven Inflammation in the Eyes of Patients with Dry Eye Disease.Diseases (Basel, Switzerland) · 2024Review
- Drug Release from Lipid Microparticles-Insights into Drug Incorporation and the Influence of Physiological Factors.Pharmaceutics · 2024Article
- Therapeutic Targets in the Management of Dry Eye Disease Associated with Sjögren's Syndrome: An Updated Review of Current Insights and Future Perspectives.Journal of clinical medicine · 2024Review
- Advances and prospects of platelet-rich plasma therapy in veterinary ophthalmology.Veterinary research communications · 2023Review
- The Comparison between the Composition of 100% Autologous Serum and 100% Platelet-Rich Plasma Eye Drops and Their Impact on the Treatment Effectiveness of Dry Eye Disease in Primary Sjogren Syndrome.Journal of clinical medicine · 2023Article
- Role of FGF10/FGFR2b Signaling in Homeostasis and Regeneration of Adult Lacrimal Gland and Corneal Epithelium Proliferation.Investigative ophthalmology & visual science · 2023Article
- Review
- Risk factors for fluctuations in corneal endothelial cell density (Review).Experimental and therapeutic medicine · 2022Review
- A Practical Approach to Severity Classification and Treatment of Dry Eye Disease: A Proposal from the Mexican Dry Eye Disease Expert Panel.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Prolonged face mask use might worsen dry eye symptoms.Indian journal of ophthalmology · 2021Article
- Establishment of functional epithelial organoids from human lacrimal glands.Stem cell research & therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye syndrome is a complex and insidious pathology with a high level of prevalence among the human population and with a consequently high impact on quality of life and economic cost. Currently, its treatment is symptomatic, mainly based on the control of lubrication and inflammation, with significant limitations. Therefore, the latest research is focused on the development of new biological strategies, with the aim of regenerating affected tissues, or at least restricting the progression of the disease, reducing scar tissue, and maintaining corneal transparency. Therapies range from growth factors and cytokines to the use of different cell sources, in particular mesenchymal stem cells, due to their multipotentiality, trophic, and immunomodulatory properties. We will review the state of the art and the latest advances and results of these promising treatments in this pathology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.